In the presented manuscript, we described the characteristics of the Polish population of patients with EGFR-mutated advanced NSCLC focusing on baseline characteristics of the patients, treatment used in first- and second-line therapy, and EGFR mutation testing practice in Poland. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.